Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma

Trial Details

NCT ID

NCT07369492

Phase

PHASE1

Sponsor

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• BAFF-R CAR-T cells

Locations (sample)

• Suzhou, China|31.30408,120.59538

Key Eligibility Criteria

• 1\. Subjects voluntarily participate in clinical research and sign informed consent.
• 2\. Subjects with CD19-negative relapsed or refractory B-cell lymphoma: a) failure to achieve CR after 6 cycles, or PR after 3 cycles, of first-lin…
• 3\. Expected survival ≥ 3 months.
• 4\. BAFF-R expression are detected on tumor cells of subjects by flow cytometry or immunohistochemistry.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.